First Documented Case of Successful Dual Therapy With Upadacitinib and Mirikizumab for Multi-Refractory Ulcerative Proctitis.

Fecha de publicación: 24/05/2025 Fecha Ahead of Print: 24/05/2025

Autores de IIS La Fe

Alejandro Mínguez Sabater

Autor
Pilar Nos Mateu

Autor

Participantes ajenos a IIS La Fe

Robles de la Osa D
Semrik NM

Grupos

Enfermedad Inflamatoria Intestinal

Abstract

This article reports the first documented case of successful dual therapy with upadacitinib (JAK inhibitor) and mirikizumab (anti-IL-23) for multi-refractory ulcerative proctitis, demonstrating clinical remission, biomarker normalization, and endoscopic improvement after failure of conventional therapies.

Datos de la publicación

ISSN/ISSNe:: 1078-0998, 1536-4844
Tipo:: Article
Páginas:: 3470-3471
DOI:: 10.1093/ibd/izaf113
PubMed:: 40411442
Factor de Impacto:: 1,706 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Robles de la Osa D:: Gastroenterology Department, University Care Complex of Palencia, Palencia, Spain
Semrik NM:: Gastroenterology Department, University Clinic Reina Fabiola, Córdoba, Argentina
Mínguez Sabater A:: IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

Instituto de Investigación. La Fe Health Research Institute (IIS La Fe), Valencia, Spain
Nos P:: IBD Unit, Gastroenterology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

Instituto de Investigación. La Fe Health Research Institute (IIS La Fe), Valencia, Spain

Keywords

combination therapy; mirikizumab; refractory ulcerative proctitis; ulcerative colitis; upadacitinib

Campos de Estudio

Cita

Cita Bibliográfica